InvestorsHub Logo
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: DewDiligence post# 2238

Sunday, 11/08/2009 6:02:16 AM

Sunday, November 08, 2009 6:02:16 AM

Post# of 3562
The more consequential events for Teva are no doubt linked to Copaxone. In addition to the ending of the 25% royalty payments to Sanofi after Apr 2010 that you've mentioned, any direct event like the M356 litigation with MNTA (Markman hearings is due in Dec), or indirect one such as FDA action on MNTA's M-Enoxaparin, would be consequential. An acquisition should be consequential as it would diversify away from Copaxone.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TEVA News